In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.
There are now 24 sites open for enrollment in the U.S and EU. The company expects to announce topline results in mid-2018.
In addition, the Vital board has formed a commercialization committee to formulate a commercial strategy in anticipation of a positive outcome for its VTL-308 Phase 3 trial.
The committee will be chaired by recently appointed board member, Faheem Hasnain, former president and CEO of Receptos and includes board members J.J. Bienaime, CEO of BioMarin Pharmaceutical; Cheryl Cohen, former chief commercial officer of Medivation; Phil Croxford, CEO of Gamma Medica; and Doug Godshall, former CEO of Heartware.
The company said it has no insight into the VTL-308 trial results other than enrollment progression, and none is expected before the anticipated mid-2018 topline readout.
